The US Court of Appeals for the Federal Circuit has affirmed a ruling of a lower court that found a patent owned by Regeneron unenforceable because of the biotech company’s inequitable conduct.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
US Court of Appeals for the Federal Circuit, Regeneron, patent, inequitable conduct, biotech, Merus